NSE ScannerComparison · NSE · data 2026-11-01
Ind-Swift Laboratories Ltd. vs Kwality Pharmaceuticals Ltd
In plain words
Size: Kwality Pharmaceuticals Ltd is about 1.1 times the market value of Ind-Swift Laboratories Ltd..
Valuation (P/E): Kwality Pharmaceuticals Ltd 44.5 vs Ind-Swift Laboratories Ltd. 38.2.
Return on equity: Kwality Pharmaceuticals Ltd 22.6% vs Ind-Swift Laboratories Ltd. 3.4%.
Profit growth over 3 years: Kwality Pharmaceuticals Ltd 51.5% a year vs Ind-Swift Laboratories Ltd. -3.2% a year.
Debt to equity: Kwality Pharmaceuticals Ltd 0.39 vs Ind-Swift Laboratories Ltd. 0.01.
Differences in the numbers, not a recommendation of either stock.
Side by side
| INDSWFTLAB | KPL | |
|---|---|---|
| Price | ₹368.2 | ₹3,475.3 |
| Market cap | ₹3,195 cr | ₹3,604 cr |
| P/E | 38.2 | 44.5 |
| P/B | 2.2 | — |
| ROE | 3.4% | 22.6% |
| ROCE | -0.2% | 31.4% |
| Debt / equity | 0.01 | 0.39 |
| Operating margin | 9.4% | 20.8% |
| Dividend yield | 0.00% | 0.00% |
| Sales growth, 3 years (yearly) | -19.6% | 26.1% |
| Profit growth, 3 years (yearly) | -3.2% | 51.5% |
| 1-year return | 260.3% | 98.9% |
| Revenue, last 12 months | ₹753 cr | ₹554 cr |
| Net profit, last 12 months | ₹84 cr | ₹81 cr |
| Latest quarter | Sept 2026 | — |
| Quarter net profit | ₹34 cr | — |
| Quarter profit vs a year earlier | +328.3% | — |
| Promoter holding | 42.93% | — |
| Health check | Average (5.8/10) | Strong (8.4/10) |
Common questions
Which has a higher P/E, Ind-Swift Laboratories Ltd. or Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd trades at the higher P/E (44.5 against 38.2). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Kwality Pharmaceuticals Ltd (22.6% against 3.4%).
Which carries more debt?
Kwality Pharmaceuticals Ltd has the higher debt-to-equity ratio (0.39 against 0.01).